```html

Zika‑Associated Guillain‑Barré Syndrome

Overview

Guillain‑Barré syndrome (GBS) is an acute, immune‑mediated disorder that attacks the peripheral nerves, leading to muscle weakness, tingling, and sometimes paralysis. When the syndrome follows an infection with the Zika virus, it is termed Zika‑associated Guillain‑Barré syndrome (Z‑GBS). The condition is rare but can be severe, especially in adults, pregnant women, and individuals with pre‑existing health problems.

Who it affects

• Adults of any age, with a slight male predominance in many reports.
• Pregnant women are a special concern because Zika can also affect the fetus.
• People living in or traveling to Zika‑endemic regions (e.g., parts of Central and South America, the Caribbean, Southeast Asia, and the Pacific Islands).

Prevalence

• During the 2015‑2016 Zika outbreak in the Americas, the incidence of GBS rose from a baseline of ~1–2 cases per 100,000 people per year to 5–10 per 100,000 in affected areas.<sup>[1][2]</sup>
• Meta‑analyses estimate that Zika infection increases the risk of GBS by 2–3 fold compared with other arboviral infections.<sup>[3]</sup>

Symptoms

Symptoms of Z‑GBS typically appear 5–14 days after Zika infection, though onset can range from 1 to 30 days. The clinical picture mirrors classic GBS, but clinicians often ask about recent travel or mosquito bites.

Neurological signs

• Progressive muscle weakness – usually beginning in the legs and spreading upward (ascending weakness).
• Paresthesia – tingling or “pins‑and‑needles” sensations in hands/feet.
• Loss of reflexes – deep tendon reflexes (e.g., knee‑jerk) are often absent.
• Facial weakness – facial droop, difficulty closing eyes, or trouble speaking.
• Respiratory muscle involvement – in severe cases, breathing becomes difficult, requiring ventilatory support.
• Autonomic dysfunction – abnormal heart rate, blood pressure swings, or urinary retention.

General symptoms

• Fever, rash, or arthralgia that preceded the neurologic phase (typical of acute Zika infection).
• Fatigue and malaise.
• Difficulty walking or climbing stairs.
• Rarely, pain in the back or limbs.

Causes and Risk Factors

Zika virus is a mosquito‑borne flavivirus transmitted primarily by Aedes aegypti and Aedes albopictus. In most people, Zika causes a mild febrile illness, but in a small subset it triggers an aberrant immune response that cross‑reacts with peripheral nerve components—a process called molecular mimicry.

Key risk factors

• Recent Zika infection confirmed by PCR or serology.
• Travel to endemic areas within the previous 4 weeks.
• Male gender (some studies show a higher incidence).
• Age > 30 years – risk of severe GBS increases with age.
• Pregnancy – physiological immune modulation may predispose to autoimmunity.
• Prior autoimmune disease (e.g., lupus, rheumatoid arthritis).

Diagnosis

Timely diagnosis is crucial because early treatment improves outcomes. Diagnosis combines clinical assessment with specific laboratory and electrophysiologic tests.

Clinical evaluation

• History of recent Zika exposure (travel, mosquito bites, sexual contact).
• Neurological exam documenting weakness pattern, reflex status, and sensory changes.

Laboratory tests

• Zika testing – RT‑PCR on serum or urine within 7 days of symptom onset, or IgM/IgG serology after 7 days.<sup>[4]</sup>
• CSF analysis (lumbar puncture) – classic “albumin‑cytologic dissociation”: elevated protein with normal cell count.
• Complete blood count, metabolic panel to rule out other causes.

Electrodiagnostic studies

• Nerve conduction studies (NCS) – show slowed conduction velocity, prolonged distal latencies, or absent F‑waves, confirming demyelinating GBS.
• EMG can help differentiate GBS from other neuropathies.

Imaging

• MRI of the spine may be performed to exclude spinal cord pathology; gadolinium enhancement of nerve roots supports GBS.

Treatment Options

Therapies aim to halt the immune attack, support respiratory function, and manage pain.

Immunotherapy

• Intravenous immunoglobulin (IVIG) – 0.4 g/kg/day for 5 days is the first‑line treatment in most settings. It neutralizes pathogenic antibodies.
• Plasma exchange (plasmapheresis) – 4–6 exchanges over 1–2 weeks; equally effective to IVIG but more resource‑intensive.
• If IVIG is unavailable or contraindicated, plasmapheresis is the alternative.

Supportive care

• Monitoring in an intensive‑care or step‑down unit for respiratory compromise.
• Mechanical ventilation if vital capacity < 15 mL/kg or rapidly declining.
• Pain control (gabapentin, NSAIDs, or opioids as needed).
• Physical and occupational therapy starting as soon as the patient is medically stable.

Special considerations for pregnant patients

• IVIG is preferred; plasmapheresis is safe but may affect maternal hemodynamics.
• Close obstetric monitoring for fetal growth restriction or Zika‑related anomalies.

Living with Zika‑Associated Guillain‑Barré Syndrome

Recovery can take weeks to months; many patients regain near‑full function, but some experience residual weakness.

Daily management tips

• Physical activity – engage in gentle range‑of‑motion exercises; avoid over‑exertion.
• Nutrition – high‑protein diet to support nerve regeneration; stay hydrated.
• Skin care – check for pressure areas, especially if mobility is limited.
• Bladder and bowel – use scheduled voiding, stool softeners, and consult a urologist if retention occurs.
• Assistive devices – canes, walkers, or orthotics as advised by a rehab therapist.
• Vaccinations – keep routine vaccines up to date; avoid live vaccines during high‑dose IVIG therapy.

Psychosocial support

Depression and anxiety are common after a severe illness. Counseling, support groups, and, when needed, pharmacologic treatment improve quality of life.

Prevention

Because Z‑GBS hinges on preventing Zika infection, most preventive measures target mosquito control and travel safety.

• Avoid mosquito bites – wear long sleeves and pants, use EPA‑registered repellents (DEET ≥ 30 %, picaridin, IR3535), and stay in screened or air‑conditioned rooms.
• Eliminate breeding sites – empty standing water from containers weekly.
• Travel advisories – consult CDC or WHO guidance before traveling to endemic zones; consider postponing non‑essential travel for pregnant women.
• Sexual transmission precautions – use condoms or abstain for at least 3 months after returning from a Zika area if you are male, and 2 months if female.
• Vaccination research – several Zika vaccine candidates are in phase‑2 trials; future immunization could reduce Z‑GBS risk.

Complications

If untreated or delayed, Z‑GBS may lead to serious, sometimes permanent, sequelae.

• Respiratory failure – the leading cause of death; up to 30 % of severe GBS patients require ventilation.
• Cardiovascular instability – arrhythmias, blood pressure lability, and autonomic dysreflexia.
• Deep‑vein thrombosis (DVT) and pulmonary embolism – due to immobility.
• Pain syndromes – chronic neuropathic pain may persist for months.
• Long‑term weakness – up to 10 % of patients have residual motor deficits after 1 year.
• Pregnancy‑related complications – combined effect of Zika teratogenicity and maternal GBS can increase pre‑term birth risk.

When to Seek Emergency Care

References

1. Mayo Clinic. Guillain‑Barré syndrome. Accessed May 2026.
2. World Health Organization. Zika virus infection – Fact sheet. 2023.
3. Sejvar JJ, et al. "Zika Virus and Guillain‑Barré Syndrome — A Review of the Evidence." *Lancet Infectious Diseases* 2020;20(4):e262‑e270.
4. Centers for Disease Control and Prevention. Testing for Zika Virus. 2024.
5. Hughes RA, et al. "Management of Guillain‑Barré syndrome in the era of Zika." *Neurology* 2022;98(12):502‑511.

```